This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AstraZeneca (AZN) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
AstraZeneca's (AZN) first-quarter results reflect a beat on both counts (revenues and earnings). AZN maintains its 2022 guidance.
Emergent's (EBS) Q1 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Emergent's (EBS) first-quarter 2022 earnings miss estimates while sales beat the mark. EBS suspends its CDMO guidance for 2022 until it gets a better picture of the COVID-19 vaccine requirements.
Repligen (RGEN) Q1 Earnings and Sales Beat Estimates, Stock Up
by Zacks Equity Research
Repligen (RGEN) reports encouraging first-quarter results with both sales and earnings beating estimates. RGEN also reduced its financial guidance for 2022
BioMarin (BMRN) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Biomarin Pharmaceutical's (BMRN) first-quarter earnings and sales beat estimates. BMRN also raises its financial guidance for 2022 Voxzogo sales by $10 million.
Eli Lilly (LLY) Beats on Q1 Earnings, Ups Sales View, Stock Rises
by Zacks Equity Research
Eli Lilly (LLY) beats first-quarter estimates for both earnings and sales and ups its sales outlook for 2022. The stock rises in pre-market trading.
NeoGenomics (NEO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
NeoGenomics (NEO) delivered earnings and revenue surprises of 13.04% and 0.90%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Deciphera Pharmaceuticals, Inc. (DCPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Deciphera Pharmaceuticals, Inc. (DCPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 Reasons to Add Deciphera (DCPH) Stock to Your Portfolio
by Zacks Equity Research
Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since approval. The recent restructuring initiative is saving costs.
The Zacks Analyst Blog Highlights Johnson & Johnson, Eli Lilly, Vertex Pharmaceuticals and Deciphera Pharmaceuticals
by Zacks Equity Research
Johnson & Johnson, Eli Lilly, Vertex Pharmaceuticals and Deciphera Pharmaceuticals have been included in this Analyst Blog.
J&J Sets in Motion Drug/Biotech Q1 Earnings: 3 Stocks to Buy
by Kinjel Shah
Investors typically look at J&J's (JNJ) results to gauge how the rest of the drug sector will fare.
Wall Street Analysts Think Deciphera Pharmaceuticals, Inc. (DCPH) Could Surge 73%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Deciphera Pharmaceuticals, Inc. (DCPH) points to a 73.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Deciphera Pharmaceuticals, Inc. (DCPH) Down 15% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Deciphera (DCPH) Q4 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Deciphera (DCPH) reports wider-than-expected loss in the fourth quarter while revenues beat estimates. Stock down is after-hours trading.
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of -1.34% and 3.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stock Q4 Earnings Due Feb 8: PFE, INCY & DCPH
by Sundeep Ganoria
Let us take a look at three biotech/drug companies that are slated to release quarterly results on Feb 8.
Analysts Estimate Deciphera Pharmaceuticals, Inc. (DCPH) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Deciphera Pharmaceuticals, Inc. (DCPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Blueprint Medicines (BPMC) Up 24.8% in Past 6 Months: Here's Why
by Zacks Equity Research
Blueprint Medicines' (BPMC) Ayvakit, approved to treat PDGFRA Exon 18 mutant gastrointestinal stromal tumors, has seen strong uptake since approval. Other pipeline candidates are also progressing well.
Blueprint Medicines' (BPMC) Ayvakit Aids Growth Amid Rivalry
by Zacks Equity Research
Blueprint Medicines' (BPMC) Ayvakit, which has been approved to treat PDGFRA Exon 18 mutant gastrointestinal stromal tumors, has seen strong uptake since approval. However, stiff competition remains a headwind.
The Zacks Analyst Blog Highlights: Vertex Pharma, Amgen, Blueprint Medicines, Deciphera Pharma and CTI BioPharma
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Vertex Pharma, Amgen, Blueprint Medicines, Deciphera Pharma and CTI BioPharma
Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Down 78.5% Since Last Earnings Report?
by Zacks Equity Research
Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biotech Stock Roundup: VRTX, AMGN's Pipeline Updates, BPMC's Acquisition & More
by Zacks Equity Research
Pipeline updates from Vertex (VRTX) and Amgen (AMGN) and other acquisition and regulatory updates have been the biotech sector's few key highlights during the past week.
Deciphera (DCPH) to Prioritize Key Pipeline Drugs, Cut Jobs
by Zacks Equity Research
Deciphera (DCPH) announces a corporate restructuring plan to prioritize development of vimseltinib and DCC-3116, streamline commercial operations and reduce workforce by almost 35%. Shares rise.
Deciphera (DCPH) Down More Than 70% in Past 3 Months: Here's Why
by Zacks Equity Research
Deciphera's (DCPH) sole marketed drug, Qinlock, is approved for treating advanced gastrointestinal stromal tumors. The recent regulatory setback for Qinlock has hurt the stock.
Deciphera (DCPH) Gets EU Nod for Qinlock in Fourth-Line GIST
by Zacks Equity Research
The European Commission approves Deciphera's (DCPH) Qinlock for the treatment of fourth-line gastrointestinal stromal tumor.
Deciphera (DCPH) Q3 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
Deciphera (DCPH) reports wider-than-expected loss and revenue miss in the third quarter. It is gearing up for multiple developments and pipeline updates in the fourth quarter.